In terms of modulating tumor cells, HDACis influence PD-L1 expression and acetylation-dependent PD-L1 nuclear translocation by targeting and inhibiting HDAC, thereby affecting tumor cell responsiveness to immune checkpoint blockade (ICB) therapies (Fig. 4D) [40, 78, 79]. This evidence concerns the gene HDAC9 and neoplasm.